{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:26:19Z","timestamp":1791300379780,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ecl.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:10:22Z","timestamp":1679386222000},"page":"547-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Management of Metabolic-Associated Fatty Liver Disease"],"prefix":"10.1016","volume":"52","author":[{"given":"Kirthika","family":"Venkatesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha Nigil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ecl.2023.02.002_bib1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic-Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"10290","key":"10.1016\/j.ecl.2023.02.002_bib2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2023.02.002_bib3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.ecl.2023.02.002_bib4","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD","volume":"19","author":"Nguyen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ecl.2023.02.002_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101111","article-title":"Genetic and epigenetic factors determining NAFLD risk","volume":"50","author":"Jonas","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.ecl.2023.02.002_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.gastro.2019.09.008","article-title":"Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease","volume":"158","author":"Hagstr\u00f6m","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.002_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/nu14010103","article-title":"Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota","volume":"14","author":"Dro\u017cd\u017c","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.ecl.2023.02.002_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jhep.2020.12.032","article-title":"NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change","volume":"74","author":"Hegarty","year":"2021","journal-title":"J\u00a0Hepatol Apr"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.002_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis","volume":"19","author":"Balakrishnan","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.ecl.2023.02.002_bib10","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.3390\/nu14214556","article-title":"Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review","volume":"14","author":"Riazi","year":"2022","journal-title":"Nutrients;"},{"issue":"6","key":"10.1016\/j.ecl.2023.02.002_bib11","first-page":"440","article-title":"Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment","volume":"2","author":"Stengel","year":"2006","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.002_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.14218\/JCTH.2021.00248","article-title":"Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update","volume":"10","author":"Alharthi","year":"2022","journal-title":"J\u00a0Clin translational Hepatol"},{"issue":"6","key":"10.1016\/j.ecl.2023.02.002_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1373\/jalm.2016.022806","article-title":"The Enhanced Liver Fibrosis (ELF) Panel: Analyte Stability Under Common Sample Storage Conditions Used in Clinical Practice","volume":"1","author":"Kennedy","year":"2017","journal-title":"The J Appl Lab Med"},{"issue":"12","key":"10.1016\/j.ecl.2023.02.002_bib14","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.3390\/biomedicines9121903","article-title":"Hepatokines and non-alcoholic fatty liver disease: linking liver pathophysiology to metabolism","volume":"9","author":"Kim","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.ecl.2023.02.002_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"issue":"28","key":"10.1016\/j.ecl.2023.02.002_bib16","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","article-title":"Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations","volume":"20","author":"Mili\u0107","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.ecl.2023.02.002_bib17","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int"},{"issue":"42","key":"10.1016\/j.ecl.2023.02.002_bib18","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ecl.2023.02.002_bib19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.002_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3748\/wjg.v29.i1.126","article-title":"Management of metabolic-associated fatty liver disease: The diabetology perspective","volume":"29","author":"Jeeyavudeen","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ecl.2023.02.002_bib21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.14218\/JCTH.2022.00052","article-title":"Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update","volume":"10","author":"Fouda","year":"2022","journal-title":"J\u00a0Clin translational Hepatol"},{"issue":"3","key":"10.1016\/j.ecl.2023.02.002_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5114\/ceh.2021.109228","article-title":"Metabolic-associated fatty liver disease and adverse maternal and fetal outcomes: a systematic review and meta-analysis","volume":"7","author":"Dyah","year":"2021","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.ecl.2023.02.002_bib23","doi-asserted-by":"crossref","first-page":"e934134","DOI":"10.12659\/MSM.934134","article-title":"A\u00a0Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health","volume":"27","author":"Ram\u00edrez-Mej\u00eda","year":"2021","journal-title":"Med Sci monitor"},{"issue":"6","key":"10.1016\/j.ecl.2023.02.002_bib24","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes care"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.002_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc diabetology"},{"issue":"6","key":"10.1016\/j.ecl.2023.02.002_bib26","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.002_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12944-021-01521-w","article-title":"Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis","volume":"20","author":"Huang","year":"2021","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ecl.2023.02.002_bib28","doi-asserted-by":"crossref","first-page":"649018","DOI":"10.3389\/fendo.2021.649018","article-title":"Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes\uff1aA Network Meta-Analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2023.02.002_bib29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.002_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: Old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.ecl.2023.02.002_bib31","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: State of Art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ecl.2023.02.002_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metab Clin Exp"},{"issue":"6","key":"10.1016\/j.ecl.2023.02.002_bib33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ecl.2023.02.002_bib34","first-page":"839275","article-title":"Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?","volume":"2013","author":"Hafeez","year":"2013","journal-title":"J\u00a0Obes"},{"issue":"10","key":"10.1016\/j.ecl.2023.02.002_bib35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nrgastro.2012.161","article-title":"The importance of the gut microbiota after bariatric surgery","volume":"9","author":"Aron-Wisnewsky","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ecl.2023.02.002_bib36","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.3390\/nu13082649","article-title":"Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis","volume":"13","author":"Cerreto","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ecl.2023.02.002_bib37","first-page":"7823182","article-title":"The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss","author":"Ruban","year":"2018","journal-title":"Gastroenterol Res Pract"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852923000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852923000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:09Z","timestamp":1760176089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852923000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0889852923000105"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2023.02.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Metabolic-Associated Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}